In emerging markets, social variables and other factors frequently restrict participation, making clinical trials inaccessible to various people. Despite the higher prevalence of some diseases and potentially varied results, marginalized people are often excluded from clinical trials and miss out on the opportunity to participate in research on potentially life-saving medicines. Archeron Clinical is therefore looking for novel approaches to enhance data collecting, lower expenses, and broaden the diversity of trial participants.
Aviruk Chakraborty launched Archeron Clinical Solutions initially as the captive unit for its CRISPR lab, a division of the Archeron group. With the lofty goal of inventing clinical trial methodologies today for a better and healthier tomorrow, Archeron Clinical Solutions was spun off as a separate SBU during the pandemic in response to repeated requests from its US research partners for the necessity of a quality CRO. Being a Founder of Archeron Group, a thought leader in the space of Artificial Intelligence and genetics-driven healthcare solutions, Aviruk is committed to offering better solutions and innovations to make a significant impact on the healthcare industry. He believes that change is the only constant for any innovation-driven organization but change must be carried out in a way that fosters trust and confidence among all stakeholders and customers.
Providing Cost-effective Clinical Trials
Archeron Clinical has developed many innovations like an AI-based patient onboarding KIOSK, hardware, and software
framework for conducting decentralized clinical trials, along with various AI/NLP algorithms for rising cost-effective solutions.
“In addition to concentrating on offering clinical research solutions to our international clients, our company is also constantly creating and refining new AI-based solutions for the CRO sector and the decentralized clinical trial ecosystem. Our primary research areas include artificial intelligence (AI), genomics, CRISPR, and medical electronics. The research helps us better comprehend our customers. We believe the next five years, from 2023 to 2028, will be the game changer due to the introduction of personalized medicines as an impact of genetic editing technologies. The next five years will also see the rise of various 5G integrated AI-based medical devices”, speaks Aviruk Chakraborty, Founder, Archeron Clinical.
With its hybrid clinical trial strategy that includes both developed and emerging markets, Archeron Clinical can provide its clients with a more thorough platform with solutions owing to its experience with AI and IoT platforms. Along with offering customer-focused solutions to ensure superior quality and zero defects, this strategy also makes a feasible global regulatory plan for the product life cycle possible. “Our wide array of services includes Clinical Operations & Project Management, Global Regulatory Service, Regulatory and medical writing, Quality assurance, Data Management, Pharmacovigilance/ Materiovigilance, Medical Monitoring, and Drug depot and logistics.
We maintain cost with the lower end of the spectrum by splitting the trial within low-cost and high-cost jurisdictions”, says Aviruk. The company’s AI-based diagnostic support system is a comprehensive, advanced visual analysis and quantification platform that assists doctors in detecting, diagnosing, and monitoring disease treatment. It can identify clinically significant pathologies in medical images for e.g, every resident in UAE has to undergo a chest X-ray for TB screening, and the AI algorithm does the preliminary analysis, which is developed and implemented by the Archeron group.
Clinical Trial Industry Is Rapidly Evolving Due To Various Disruptive Innovations Like Genomics, Iot, AI, And CRISPR In A Positive Direction
“Our main concentration is on US clients but over the past two years, we have broadened our clientele to include businesses from the US, Europe, the Middle East, South Korea, and Australia”, shares a member of the business team. Archeron Clinical also provides comprehensive solutions for US Department of Defence-funded, Nsdaq-listed US pharmaceutical companies. The company's long-term plan anticipates significant development in the medical device market and an IPO in 2024.
.jpg "Overcoming the Hurdles of Scaling a Startup")
